NeuroSense Therapeutics Updates Investors with New Presentation
Ticker: NRSNW · Form: 6-K · Filed: Apr 10, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Apr 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: presentation, investor-relations, 6-K
TL;DR
NeuroSense dropped a new investor deck, check Exhibit 99.1 for the latest.
AI Summary
NeuroSense Therapeutics Ltd. has filed a Form 6-K on April 10, 2024, to furnish an updated presentation about its business. This presentation is being provided as Exhibit 99.1 to the report and contains summary information for investors.
Why It Matters
This filing provides investors with updated information on NeuroSense Therapeutics' business strategy and progress, which could influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing providing an updated presentation, not indicating significant new risks or material changes.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report
- April 10, 2024 (date) — Filing date
- Exhibit 99.1 (document) — Updated presentation
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to furnish an updated presentation about NeuroSense Therapeutics Ltd.'s business, as required for foreign private issuers.
When was this Form 6-K filed?
This Form 6-K was filed on April 10, 2024.
What is included as an exhibit to this filing?
Exhibit 99.1, an updated presentation about the Company's business, is included as an exhibit to this filing.
Does NeuroSense Therapeutics file annual reports under Form 20-F or 40-F?
NeuroSense Therapeutics indicates that it files annual reports under Form 20-F.
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd. is headquartered at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
Filing Stats: 245 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2024-04-10 09:00:47
Filing Documents
- ea0203572-6k_neurosense.htm (6-K) — 10KB
- ea020357201ex99-1_neurosense.htm (EX-99.1) — 45KB
- ex99-1_001.jpg (GRAPHIC) — 577KB
- ex99-1_002.jpg (GRAPHIC) — 965KB
- ex99-1_003.jpg (GRAPHIC) — 412KB
- ex99-1_004.jpg (GRAPHIC) — 394KB
- ex99-1_005.jpg (GRAPHIC) — 573KB
- ex99-1_006.jpg (GRAPHIC) — 476KB
- ex99-1_007.jpg (GRAPHIC) — 576KB
- ex99-1_008.jpg (GRAPHIC) — 407KB
- ex99-1_009.jpg (GRAPHIC) — 718KB
- ex99-1_010.jpg (GRAPHIC) — 426KB
- ex99-1_011.jpg (GRAPHIC) — 488KB
- ex99-1_012.jpg (GRAPHIC) — 475KB
- ex99-1_013.jpg (GRAPHIC) — 479KB
- ex99-1_014.jpg (GRAPHIC) — 337KB
- ex99-1_015.jpg (GRAPHIC) — 462KB
- ex99-1_016.jpg (GRAPHIC) — 391KB
- ex99-1_017.jpg (GRAPHIC) — 341KB
- ex99-1_018.jpg (GRAPHIC) — 502KB
- ex99-1_019.jpg (GRAPHIC) — 368KB
- ex99-1_020.jpg (GRAPHIC) — 399KB
- ex99-1_021.jpg (GRAPHIC) — 420KB
- ex99-1_022.jpg (GRAPHIC) — 477KB
- ex99-1_023.jpg (GRAPHIC) — 315KB
- ex99-1_024.jpg (GRAPHIC) — 455KB
- ex99-1_025.jpg (GRAPHIC) — 317KB
- ex99-1_026.jpg (GRAPHIC) — 452KB
- ex99-1_027.jpg (GRAPHIC) — 406KB
- ex99-1_028.jpg (GRAPHIC) — 521KB
- ex99-1_029.jpg (GRAPHIC) — 454KB
- ex99-1_030.jpg (GRAPHIC) — 419KB
- ex99-1_031.jpg (GRAPHIC) — 408KB
- ex99-1_032.jpg (GRAPHIC) — 415KB
- ex99-1_033.jpg (GRAPHIC) — 552KB
- ex99-1_034.jpg (GRAPHIC) — 624KB
- ex99-1_035.jpg (GRAPHIC) — 450KB
- ex99-1_036.jpg (GRAPHIC) — 474KB
- ex99-1_037.jpg (GRAPHIC) — 777KB
- ex99-1_038.jpg (GRAPHIC) — 515KB
- ex99-1_039.jpg (GRAPHIC) — 407KB
- ex99-1_040.jpg (GRAPHIC) — 475KB
- ex99-1_041.jpg (GRAPHIC) — 502KB
- ex99-1_042.jpg (GRAPHIC) — 527KB
- 0001213900-24-031747.txt ( ) — 27777KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: April 10, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2